An Evaluation Of The Effect Of Saffron Supplementation On The Antibody Titer To Heat-shock Protein (HSP) 70, HsCRP And Spirometry Test In Patients With Mild And Moderate Persistent Allergic Asthma: A Triple-blind, Randomized Placebo-controlled Trial
|Values||median (25th, 75th percentiles Placebo: before 0.54 (0.43–0.78), after 1.00 (0.73–1.39). Saffron: before 0.46 (0.35–0.82), after 0.37 (0.25–0.56)|
|Trial Design||Randomized trial|
|Trial Length||1-6 months|
|Number of Subjects||80|
|Age Range||18-29, 30-44, 45-64|
In a randomized, triple-blind, placebo-controlled trial, 80 participants with mild or moderate allergic asthma took 100 mg of saffron or placebo for 8 weeks.
The primary outcome was lung function as measured by spirometry and FEV1, FVC, FEV1/FVC ratio, and FEF25-75 were improved. Hs-CRP was dramatically reduced and anti-HSP70 antibodies were reduced somewhat in the saffron group while they were increased in the placebo group, the difference being statistically significant.
The trial was preregistered: IRCT2017012132081N2